Omeros | OMER - سود ناخالص در فروش





سود ناخالص در فروش تغییر دادن تاریخ
Adma Biologics USD 88.82M 13.19M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Cytokinetics USD 17.76M 15.82M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Heron Therapeutics USD 29.47M 3.17M 2025-12
Immunic 0 0 2025-03
Insmed USD 217.69M 106.25M 2025-12
Knight Therapeutics CAD 64.72M 8.91M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
Omeros USD -33.16M 18.52M 2024-06
Pacira USD 142.25M 11.34M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Rockwell Medical USD 4.55M 1.49M 2024-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12
Xoma 992K 846K 2024-06